Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.57 |
| ▸ | SCD | O00767 | 4/20 | 0.53 |
| ▸ | SCD5 | Q86SK9 | 3/20 | 0.53 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL535098 | 0.95 | RIPK1 (0.52) | RIPK1SCDSCD5ADAM17HSP90AA1 | |
| SCHEMBL1853141 | 0.90 | RIPK1 (0.69) | RIPK1SCDSCD5HSP90AA1HSP90AB1 | |
| SCHEMBL17558248 | 0.90 | RIPK1 (0.69) | RIPK1SCDSCD5HSP90AA1HSP90AB1 | |
| SCHEMBL1847627 | 0.90 | RIPK1 (0.69) | RIPK1SCDSCD5HSP90AA1HSP90AB1 | |
| SCHEMBL27574946 | 0.85 | RIPK1 (0.62) | RIPK1SCDSCD5HSP90AA1HSP90AB1 | |
| SCHEMBL216202 | 0.85 | RIPK1 (0.62) | RIPK1SCDSCD5HSP90AA1HSP90AB1 | |
| SCHEMBL27574934 | 0.85 | RIPK1 (0.62) | RIPK1SCDSCD5HSP90AA1HSP90AB1 | |
| Water SCHEMBL27700791 | 0.83 | RIPK1 (0.60) | RIPK1SCDSCD5HSP90AA1HSP90AB1 | |
| SCHEMBL17142323 | 0.82 | RIPK1 (0.55) | RIPK1SCDSCD5HSP90AA1HSP90AB1 | |
| SCHEMBL17142311 | 0.82 | TRPA1 (0.51) | RIPK1SCD5HSP90AA1HSP90AB1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093246-B2 | potent deoxycytidine kinase inhibitors; O-linked pyrimidin-4-amine-based compounds | LEXICON PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20080146571-A1 | O-LINKED PYRIMIDIN-4-AMINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE TO TREAT CANCER | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146571-A1 | O-LINKED PYRIMIDIN-4-AMINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE TO TREAT CANCER | DPYD, DHFR, TYMP | RIPK1 4697/4885SCD 3905/4885SCD5 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.